Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Spilman, Patricia R. | Corset, Veronique | Gorostiza, Olivia | Poksay, Karen S. | Galvan, Veronica | Zhang, Junli | Rao, Rammohan | Peters-Libeu, Clare | Vincelette, Jon | McGeehan, Andrew | Dvorak-Ewell, Melita | Beyer, Janine | Campagna, Jesus | Bankiewicz, Krystof | Mehlen, Patrick | John, Varghese | Bredesen, Dale E.
Article Type: Research Article
Abstract: Recent studies have shown that inoculation of susceptible mice with amyloid-β (Aβ) peptides accelerates Aβ deposition in the brain, supporting the idea that Aβ may be self-amplifying; however, the exact mechanism is not understood. Here we provide evidence that Aβ may self-amplify, in part, by inhibiting α-secretase ADAM10 (a disintegrin and metalloprotease) cleavage of full-length Aβ precursor protein (FL AβPP) and therefore allow greater β-secretase processing, and that Aβ itself is a substrate for ADAM10. Exposure of primary neuronal cultures from PDAβPP mice to exogenous rat Aβ1- 40 resulted in increased de novo human Aβ1-42 production and exposure …of cells to Aβ decreased production of ADAM10 cleavage product soluble AβPPα (sAβPPα). In a cell-free assay, Aβ decreased ADAM10 cleavage of the chimeric substrate MBP-AβPPC125 and Aβ itself was apparently cleaved by the enzyme. The axonal guidance and trophic factor netrin-1, however, reduced the Aβ1- 40 -induced Aβ1-42 increase, increased sAβPPα, and reversed the Aβ-induced sAβPPα decrease in vitro . In vivo , induction of netrin-1 expression in PDAβPPSwe/Ind transgenic mice resulted in reductions in both Aβ1-42 and Aβ1- 40 , and ICV delivery of netrin-1 to PDAβPPSwe/Ind mice increased sAβPPα, decreased Aβ, and improved working memory. Finally, to support further study of netrin-1’s potential as a therapeutic for Alzheimer’s disease, pilot gene therapy studies were performed and a netrin mimetic peptide synthesized and tested that, like netrin, can increase sAβPPα and decrease Aβ1-42 in vitro . Taken together, these data provide mechanistic insights into Aβ self-amplification and the ability of netrin-1 to disrupt it. Show more
Keywords: Aβ1-42, AβPP, amplification, CED, inducible, mimetic, netrin-1, sAβPPα
DOI: 10.3233/JAD-151046
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 223-242, 2016
Authors: Ontiveros-Torres, Miguel Ángel | Labra-Barrios, María Luisa | Díaz-Cintra, Sofía | Aguilar-Vázquez, Azucena Ruth | Moreno-Campuzano, Samadhi | Flores-Rodríguez, Paola | Luna-Herrera, Claudia | Mena, Raúl | Perry, George | Florán-Garduño, Benjamín | Luna-Muñoz, José | Luna-Arias, Juan Pedro
Article Type: Research Article
Abstract: Alzheimer’s disease (AD) is a degenerative and irreversible disorder whose progressiveness is dependent on age. It is histopathologically characterized by the massive accumulation of insoluble forms of tau and amyloid-β (Aβ) asneurofibrillary tangles and neuritic plaques, respectively. Many studies have documented that these two polypeptides suffer several posttranslational modifications employing postmortem tissue sections from brains of patients with AD. In order to elucidate the molecular mechanisms underlying the posttranslational modifications of key players in this disease, including Aβ and tau, several transgenic mouse models have been developed. One of these models is the 3×Tg-AD transgenic mouse, carrying three transgenes encoding …APPSWE, S1M146V, and TauP301L proteins. To further characterize this transgenicmouse, we determined the accumulation of fibrillar Aβ as a function of age in relation to the hyperphosphorylation patterns of TauP301L at both its N- and C-terminus in the hippocampal formation by immunofluorescence and confocal microscopy. Moreover, we searched for the expression of activated protein kinases and mediators of inflammation by western blot of wholeprotein extracts from hippocampal tissue sections since 3 to 28 months as well. Our results indicate that the presence of fibrillar Aβ deposits correlates with a significant activation of astrocytes and microglia in subiculum and CA1 regions of hippocampus. Accordingly, we also observed a significant increase in the expression of TNF-α associated to neuritic plaques and glial cells. Importantly, there is an overexpression of the stress activated protein kinases SAPK/JNK and Cdk-5 in pyramidal neurons, which might phosphorylate several residues at the C-terminus of TauP301L. Therefore, the accumulation of Aβ oligomers results in an inflammatory environment that upregulates kinases involved in hyperphosphorylation of TauP301L polypeptide. Show more
Keywords: Amyloid-β, hippocampus, inflammation, TauP301L, 3×Tg-AD transgenic mouse
DOI: 10.3233/JAD-150837
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 243-269, 2016
Authors: Fernández-Blázquez, Miguel A. | Ávila-Villanueva, Marina | Maestú, Fernando | Medina, Miguel
Article Type: Research Article
Abstract: Background: Alzheimer’s disease (AD) is a silent disorder that needs the earliest possible intervention in order to reduce its high economic and social impact. It has been recently suggested that subjective cognitive decline (SCD) appears at preclinical stages many years before the onset of AD. Therefore, SCD could become an ideal target for early therapeutic intervention. Objective: The goal of this study was to evaluate the clinical significance of SCD on the conversion from a cognitively healthy stage to a mild cognitive impairment (MCI) in one-year follow-up. Methods: A total of 608 cognitively intact individuals …from the Vallecas Project’s cohort, a community-based prospective study to identify early markers of AD, were enrolled in this study. Participants were classified in three groups: i) No Complaints (NCg), ii) Subjects with complaints in one or more cognitive domains (SCDg), and iii) Subjects who, besides complaints, fulfilled the features of SCD Plus proposed by the International Working Group of SCD (SCD-Pg). Results: Individuals were followed up for a mean of 13.1 months (range 10.7–22.4). During this time, 41 volunteers developed MCI (6.7% of total sample). The conversion rate for SCD-Pg (18.9%) was significantly higher than SCDg (5.6%) and NCg (4.9%). Conclusion: Specific features associated with SCD may help to identify individuals at high risk of fast conversion to MCI. These results highlight the importance of a close follow-up of subjects with SCD-P and include them in early intervention programs because of their increased risk for the development of MCI. Show more
Keywords: Aging, Alzheimer’s disease, cognitive symptoms, dementia, mild cognitive impairment, subjective cognitive decline
DOI: 10.3233/JAD-150956
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 271-281, 2016
Authors: Gramunt, Nina | Sánchez-Benavides, Gonzalo | Buschke, Herman | Diéguez-Vide, Faustino | Peña-Casanova, Jordi | Masramon, Xavier | Fauria, Karine | Gispert, Juan D. | Molinuevo, José L.
Article Type: Research Article
Abstract: Background: The Memory Binding Test (MBT) is emerging as a promising tool for the detection of subtle memory impairment suggestive of Alzheimer’s disease (AD). For such a test to be widely accessed and used, the availability of both alternate forms and language adaptations is required. Objectives: To develop a thorough methodology for obtaining alternate forms (A and B) of the MBT in Spanish and Catalan and to assess their equivalence. Method: According to the original development of the test, frequency was taken as the lexical variable of reference for the Spanish and Catalan adaptations. A …crossed design protocol by form and language was used to compare the MBT results in a sample of 290 cognitively normal middle-aged participants. Pairwise Intraclass Correlation Coefficients (ICCs) were calculated among the six possible combinations. Results: The Spanish and Catalan lists of words for the MBT A and B resulting from the adaptation process as well as the original lists in English are presented. ICC indices for the comparisons between forms and languages ranged from 0.56 to 0.82. Conclusion: The MBT A and B in Spanish and Catalan showed similar outcomes and can be considered equivalent. Moreover, the thorough methodology presented here for the transcultural adaptation and equivalence study, could serve as a model for future adaptations of the MBT and other verbal tests. Show more
Keywords: Alzheimer–s disease, cognition, episodic memory, neuropsychological assessment, preclinical, psycholinguistics
DOI: 10.3233/JAD-151175
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 283-293, 2016
Authors: Teich, Andrew F. | Sakurai, Mikako | Patel, Mitesh | Holman, Cameron | Saeed, Faisal | Fiorito, Jole | Arancio, Ottavio
Article Type: Research Article
Abstract: Phosphodiesterase 5 (PDE5) is a critical component of the cGMP-PKG axis of cellular signaling in neurons, and inhibition of PDE5 has been shown to be therapeutic in a wide range of neurologic conditions in animal models. However, enthusiasm for PDE5 inhibitors in humans is limited by data suggesting that PDE5 may not exist in human neurons. Here, we first show that past attempts to quantify PDE5 mRNA were flawed due to the use of incorrect primers, and that when correct primers are used, PDE5 mRNA is detectable in human brain tissue. We then show that PDE5 protein exists in human …brain by western blot and ELISA. Most importantly, we performed immunohistochemistry and demonstrate that PDE5 is present in human neurons. We hope that this work will trigger a renewed interest in the development of PDE5 inhibitors for neurologic disease. Show more
Keywords: Alzheimer’s disease, memory, PDE5 inhibitors, phosphodiesterase 5
DOI: 10.3233/JAD-151104
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 295-302, 2016
Authors: Sánchez, Alba | Maseda, Ana | Marante-Moar, M. Pilar | de Labra, Carmen | Lorenzo-López, Laura | Millán-Calenti, José Carlos
Article Type: Research Article
Abstract: The objective of this study was to compare the effects of a multisensory stimulation environment (MSSE) and individualized music sessions on agitation, emotional and cognitive status, and dementia severity in a sample of institutionalized patients with severe dementia. Twenty-two participants with a diagnosis of severe or very severe dementia were randomly assigned to two groups: MSSE and individualized music sessions. Both groups participated in two 30-min weekly sessions over 16 weeks. Outcomes were agitation (Cohen-Mansfield Agitation Inventory, CMAI), mood (Cornell Scale for Depression in Dementia, CSDD), anxiety (Rating Anxiety in Dementia, RAID), cognitive function (Severe Mini-Mental State Examination, SMMSE), and …the overall severity of dementia (Bedford Alzheimer Nursing Severity Scale, BANS-S). They were assessed at baseline (pre-trial), in the middle (mid-trial), at the end of the intervention (post-trial), and 8 weeks after the intervention (follow-up). Patients in the MSSE group showed significant improvement in their RAID and BANS-S scores compared with the individualized music group post- versus pre-trial. With regard to agitation, there was improvement during the intervention in both the MSSE and individualized music groups in the CMAI total score after 16 weeks of intervention, with no significant differences between the groups. The results suggest that MSSE could have better effects on anxiety symptoms and dementia severity in comparison with individualized music sessions in elderly patients with severe dementia. Show more
Keywords: Dementia, elderly, individualized music, multisensory environments, multisensory stimulation, randomized controlled trial, Snoezelen
DOI: 10.3233/JAD-151150
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 303-315, 2016
Authors: Matura, Silke | Prvulovic, David | Hartmann, Daniel | Scheibe, Monika | Sepanski, Beate | Butz, Marius | Oertel-Knöchel, Viola | Knöchel, Christian | Karakaya, Tarik | Fußer, Fabian | Hattingen, Elke | Pantel, Johannes
Article Type: Research Article
Abstract: The apolipoprotein E (ApoE) ɛ 4 allele is a well-established genetic risk factor for sporadic Alzheimer’s disease. Some evidence suggests a negative role of the ApoE ɛ 4 allele for cognitive performance in late life, while beneficial effects on cognition have been shown in young age. We investigated age-related effects of the ApoE gene on brain function by assessing cognitive performance, as well as functional activation patterns during retrieval of Face-Name pairs in a group of young (n = 50; age 26.4±4.6 years, 25 ɛ 4 carriers) and old (n = 40; age 66.1±7.0 years, 20 ɛ 4 carriers) participants. A cross-sectional …factorial design was used to examine the effects of age, ApoE genotype, and their interaction on both cognitive performance and the blood oxygenation level dependent (BOLD) brain response during retrieval of Face-Name pairs. While there were no genotype-related differences in cognitive performance, we found a significant interaction of age and ApoE genotype on task-related activation bilaterally in anterior cingulate gyrus and superior frontal gyrus, as well as left and right insula. Old age was associated with increased activity in ɛ 4 carriers. The increased BOLD response in old ɛ 4 carriers during retrieval could indicate a neurocognitive disadvantage associated with the ɛ 4 allele with increasing age. Furthermore, recruitment of neuronal resources resulted in enhanced memory performance in young ɛ 4 carriers, pointing to a better neurofunctional capacity associated with the ApoE4 genotype in young age. Show more
Keywords: Apolipoprotein 4, brain, functional MRI, memory
DOI: 10.3233/JAD-150990
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 317-331, 2016
Authors: Isla, Arturo G. | Vázquez-Cuevas, Francisco Gabriel | Peña-Ortega, Fernando
Article Type: Research Article
Abstract: Exercise is becoming a promising therapeutic approach to prevent alterations both in Alzheimer’s disease (AD) patients and in transgenic models of AD. This neuroprotection has been associated with changes in hippocampal structure and function, as well as with the reduction of amyloid-β (Aβ) production and accumulation. However, whether exercise produces lasting changes in hippocampal population activity and renders it resistant to Aβ-induced network dysfunction is still unknown. Thus, we tested whether voluntary exercise changes hippocampal population activity and prevents its alteration in the presence of Aβ, which has been associated to glycogen synthase kinase-3β (GSK3β) activation. We found that the …hippocampal population activity recorded in slices obtained from mice that exercised voluntarily (with free access to a running wheel for 21 days) exhibits higher power and faster frequency composition than slices obtained from sedentary animals. Moreover, the hippocampal network of mice that exercised becomes insensitive to Aβ-induced inhibition of spontaneous population activity. This protective effect correlates with the inability of Aβ to activate GSK3β, is mimicked by GSK3β inhibition with SB126763 (in slices obtained from sedentary mice), and is abolished by the inhibition of PI3K with LY294002 (in slices obtained from mice that exercised). We conclude that voluntary exercise produces a lasting protective state in the hippocampus, maintained in hippocampal slices by a PI3K-dependent mechanism that precludes its functional disruption in the presence of Aβ by avoiding GSK3β activation. Show more
Keywords: Amyloid-β, GSK3β, hippocampus, PI3K, spontaneous population activity, voluntary-exercise
DOI: 10.3233/JAD-150352
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 333-343, 2016
Authors: Homma, Akira | Atarashi, Hirotsugu | Kubota, Naoki | Nakai, Kenya | Takase, Takao
Article Type: Research Article
Abstract: Background: Donepezil is an established treatment for mild, moderate, and severe Alzheimer’s disease (AD). An international study demonstrated superior efficacy of sustained release (SR) 23 mg/day donepezil over immediate release (IR) 10 mg/day donepezil for cognitive function, but not global function in moderate-to-severe AD. Objective: To demonstrate the superiority of SR 23 mg/day donepezil over IR 10 mg/day donepezil in Japanese patients with severe AD (SAD). Methods: In this multicenter, randomized, double-blind, parallel-group study, Japanese outpatients with SAD were randomly assigned to continue IR 10 mg/day or switch to SR 23 mg/day for 24 weeks. Endpoints included the Severe Impairment Battery …(SIB), Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus), and safety. Results: Overall, 166 and 185 patients were randomized to receive IR 10 mg/day and SR 23 mg/day, respectively. SR 23 mg/day was not statistically superior to IR 10 mg/day by SIB (least squares mean difference [LSMD]: 0.0; 95% confidence interval [CI]: –1.7, 1.8; p = 0.981) or CIBIC-plus (LSMD: 0.2; 95% CI: 0.0, 0.4; p = 0.080). Common adverse events in the SR 23 mg group were decreased appetite, vomiting, diarrhea, and contusion. Safety findings were consistent with known safety profiles of donepezil. Conclusion: SR 23 mg/day donepezil was not superior to IR 10 mg/day donepezil regarding the efficacy endpoints for Japanese SAD. Considering that a 10 mg/day dose is approved for SAD in Japan, the present findings suggest that IR 10 mg/day donepezil is the optimal dosage for Japanese patients with SAD. Show more
Keywords: Alzheimer’s disease, cholinesterase inhibitors, donepezil, double-blind study, Japan
DOI: 10.3233/JAD-151149
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 345-357, 2016
Authors: Tramutola, Antonella | Pupo, Gilda | Di Domenico, Fabio | Barone, Eugenio | Arena, Andrea | Lanzillotta, Chiara | Broekaart, Diede | Blarzino, Carla | Head, Elizabeth | Butterfield, D. Allan | Perluigi, Marzia
Article Type: Research Article
Abstract: Down syndrome (DS) is the most common genetic cause of intellectual disability, resulting from trisomy of chromosome 21. The main feature of DS neuropathology includes early onset of Alzheimer’s disease (AD), with deposition of senile plaques and tangles. We hypothesized that apoptosis may be activated in the presence of AD neuropathology in DS, thus we measured proteins associated with upstream and downstream pathways of p53 in the frontal cortex from DS cases with and without AD pathology and from Ts65Dn mice, at different ages. We observed increased acetylation and phosphorylation of p53, coupled to reduced MDM2/p53 complex level and lower …levels of SIRT1. Activation of p53 was associated with a number of targets (BAX, PARP1, caspase-3, p21, heat shock proteins, and PGC1α ) that were modulated in both DS and DS/AD compared with age-matched controls. In particular, the most relevant changes (increased p-p53 and acetyl-p53 and reduced formation of MDM2/p53 complex) were found to be modified only in the presence of AD pathology in DS. In addition, a similar pattern of alterations in the p53 pathway was found in Ts65Dn mice. These results suggest that p53 may integrate different signals, which can result in a pro-apoptotic-phenotype contributing to AD neuropathology in people with DS. Show more
Keywords: Apoptosis, caspase, p53, sirtuins, Ts65Dn mouse model, trisomy 21
DOI: 10.3233/JAD-151105
Citation: Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 359-371, 2016
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]